The association between clinical features of asthma and impact of one-year sublingual immunotherapy on immunological system of atopic children Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Study of therapeutics effects of montelukast in asthmatic children Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Novel proteomic biomarkers in the evaluation of childhood asthma Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013
Refined severity assessment of asthmatic children using molecular allergy diagnostics Source: Annual Congress 2013 –Uncontrolled and severe asthma in children Year: 2013
U-BIOPRED asthma cohort: Inflammatory markers and corticosteroid use Source: Annual Congress 2013 –Novel mechanisms for established drugs for asthma and COPD management Year: 2013
A pilot study for markers which can reflect asthmatic activity before and after reduction of inhaled corticosteroids Source: Annual Congress 2013 –Assessment of airway inflammation by exhaled gases Year: 2013
P-PiXel: A ’real-life’ evaluation of omalizumab use in asthmatic patients Source: International Congress 2016 – Asthma management Year: 2016
One-year sublingual immunotherapy in asthmatic children do not influence on basophil’s CD203c stimulated and spontaneous expression Source: Annual Congress 2013 –Monitoring asthma: genes, cells and molecules Year: 2013
Efficacy of omalizumab in allergic asthma by asthma severity and eosinophilic status Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis Year: 2015
Systemic cytokine signaling via IL-17 and its relation to clinical characteristics in children with asthma Source: International Congress 2015 – Paediatric asthma and allergy: lung function and biomarkers Year: 2015
Global evaluation of treatment effectiveness (GETE) is an accurate predictor of response to omalizumab in patients with severe allergic asthma: A pooled analysis Source: International Congress 2014 – Intervening in allergic asthma Year: 2014
Children with severe asthma can start allergen immunotherapy after controlling asthma with omalizumab Source: International Congress 2014 – More paediatric asthma Year: 2014
Based on what parameters of clinical remission should inhaled corticosteroids be stopped in children with asthma? Source: Annual Congress 2013 –The best of paediatric asthma and allergy Year: 2013
Bronchial asthma (BA) pharmacogenetic profile and therapeutic resistance in slavic population Source: Annual Congress 2013 –Is it really asthma? Year: 2013
Prediction of asthma control and treatment changes in obstructive asthmatic children Source: International Congress 2016 – Techniques and tools in paediatric asthma Year: 2016
Real-world outcomes in patients receiving omalizumab for allergic asthma in India: Analysis by baseline IgE level Source: Annual Congress 2013 –Treatment of asthma Year: 2013
The role of allergen immunotherpy in children with mild to moderate asthma Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016
Clinical, functional and inflammatory characteristics in patients with paucigranulocytic asthma Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016
Asthma-associated factors - Potential predictive markers for patients stratification, personalized treatments and prevention Source: International Congress 2016 – Asthma points to ponder Year: 2016
TH 2 specific biomarker profile determines steroid responsiveness in severe asthma Source: Annual Congress 2013 –Biomarkers in asthma and COPD Year: 2013